Aus­tralia re­clas­si­fies psy­che­delics to fa­cil­i­tate med­ical use, as ad­vo­cates push for sim­i­lar move in US

Aus­tralia’s Ther­a­peu­tic Goods Ad­min­is­tra­tion (TGA) has re­clas­si­fied two psy­che­del­ic sub­stances to fa­cil­i­tate their use as med­i­cines for cer­tain men­tal health con­di­tions, a move that some ad­vo­cates say could serve as an ex­am­ple for the US.

Aus­tralia an­nounced in Feb­ru­ary that start­ing Ju­ly 1, au­tho­rized psy­chi­a­trists can pre­scribe drugs con­tain­ing psilo­cy­bin, an ac­tive sub­stance in “mag­ic mush­rooms,” and MD­MA for treat­ment-re­sis­tant de­pres­sion and post-trau­mat­ic stress dis­or­der, re­spec­tive­ly. Those are the on­ly two con­di­tions for which TGA has said there is “cur­rent­ly suf­fi­cient ev­i­dence for po­ten­tial ben­e­fits.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER